InVivoSIM anti-human FOLR1 (Mirvetuximab Biosimilar)

Catalog #SIM0071
Clone:
Mirvetuximab
Reactivities:
Human

$235.00 - $8,140.00

$235.00 - $8,140.00

Choose an Option...
  • 100 mg - $8,140.00
  • 50 mg - $4,574.00
  • 25 mg - $3,182.00
  • 5 mg - $911.00
  • 1 mg - $235.00
  • Custom Amount (Quotes Only)
In stock
Only %1 left

Product Details

This non-therapeutic biosimilar antibody uses the same variable regions as the therapeutic antibody mirvetuximab, making it ideal for research use. Mirvetuximab is a chimeric human IgG1 monoclonal antibody targeting folate receptor 1 (FOLR1), also known as folate receptor α (FRα) and folate-binding protein 1 (Fbp1). FOLR1 is a glycosylphosphatidylinositol (GPI)-anchored, high-affinity, low-throughput surface receptor for folate transport. The FOLR1-bound folate from the cell surface is brought into the cell through endocytosis. FOLR1 plays a significant role in maintaining the integrity of the genome (i.e., DNA metabolism), cell proliferation, and intracellular signaling. FOLR1’s expression is generally restricted to the luminal (apical) surface of polarized epithelia, including proximal renal tubules, lung pneumocytes, uterine appendages, epididymis, bronchial glands, placental trophoblasts, and choroid plexus (a network of blood vessels and specialized cells within the ventricles of the brain). Compared to the normal tissues, the expression of FOLR1 is more prevalent in several epithelial cancers, e.g., ovarian cancer, non-small-cell lung cancer, colon cancer, etc., making it an excellent prognostic marker as well as a target for anti-cancer therapeutics. FOLR1’s role is rapidly evolving in precision medicine, and the current FOLR1-targeted experimental therapeutics include small-molecule-drug conjugates, CAR-T cells, vaccines, and antibody-drug conjugates (ADCs) such as mirvetuximab soravtansine. The ADC mirvetuximab soravtansine contains a mirvetuximab antibody conjugated to the cytotoxic maytansinoid DM4 via a cleavable linker, where it binds FOLR1 on tumor cells, gets internalized, and delivers DM4 to disrupt microtubule dynamics and induce apoptosis. This mirvetuximab biosimilar is an unconjugated antibody only, and it has a great binding specificity and high affinity for human FOLR1.

Specifications

Isotype Human IgG1, Īŗ
Recommended Dilution Buffer InVivoPure pH 7.0 Dilution Buffer
Mutations E356D/M358L/KDel
Immunogen Human FOLR1
Reported Applications Functional assays
Flow cytometry
Immunohistochemistry
ELISA
Western blot
Formulation PBS, pH 7.0
Contains no stabilizers or preservatives
Endotoxin <0.5EU/mg (<0.0005EU/μg)
Determined by LAL gel clotting assay
Aggregation <5%
Determined by SEC
Purity >95%
Determined by SDS-PAGE
Sterility 0.2 µm filtration
Production Purified from cell culture supernatant in an animal-free facility
Purification Protein A
Molecular Weight 150 kDa
Murine Pathogen Tests Ectromelia/Mousepox Virus: Negative
Hantavirus: Negative
K Virus: Negative
Lactate Dehydrogenase-Elevating Virus: Negative
Lymphocytic Choriomeningitis virus: Negative
Mouse Adenovirus: Negative
Mouse Cytomegalovirus: Negative
Mouse Hepatitis Virus: Negative
Mouse Minute Virus: Negative
Mouse Norovirus: Negative
Mouse Parvovirus: Negative
Mouse Rotavirus: Negative
Mycoplasma Pulmonis: Negative
Pneumonia Virus of Mice: Negative
Polyoma Virus: Negative
Reovirus Screen: Negative
Sendai Virus: Negative
Theiler’s Murine Encephalomyelitis: Negative
Storage The antibody solution should be stored at the stock concentration at 4°C. Do not freeze.